Envestnet Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $44.2M | Buy |
262,192
+43,482
| +20% | +$6.45M | 0.01% | 932 |
|
|
2026
Q1 | $28.8M | Buy |
218,710
+11,979
| +6% | +$1.59M | 0.01% | 1101 |
|
|
2025
Q4 | $29.3M | Buy |
206,731
+3,885
| +2% | +$563K | 0.01% | 1011 |
|
|
2025
Q3 | $28.5M | Buy |
202,846
+4,807
| +2% | +$651K | 0.01% | 1062 |
|
|
2025
Q2 | $24.9M | Buy |
198,039
+75,733
| +62% | +$8.69M | 0.01% | 1122 |
|
|
2025
Q1 | $13.5M | Sell |
122,306
-80,904
| -40% | -$10.2M | ﹤0.01% | 1452 |
|
|
2024
Q4 | $27.7M | Sell |
203,210
-30,330
| -13% | -$3.75M | 0.01% | 996 |
|
|
2024
Q3 | $26.9M | Buy |
233,540
+30,747
| +15% | +$4.22M | 0.01% | 1011 |
|
|
2024
Q2 | $27.9M | Buy |
202,793
+3,396
| +2% | +$466K | 0.01% | 931 |
|
|
2024
Q1 | $27.5M | Sell |
199,397
-189
| -0.1% | -$25.8K | 0.01% | 932 |
|
|
2023
Q4 | $26.3M | Buy |
199,586
+6,742
| +3% | +$776K | 0.01% | 887 |
|
|
2023
Q3 | $21.7M | Buy |
192,844
+110,624
| +135% | +$11.6M | 0.01% | 933 |
|
|
2023
Q2 | $7.75M | Sell |
82,220
-324,562
| -80% | -$31.7M | ﹤0.01% | 1448 |
|
|
2023
Q1 | $12M | Buy |
406,782
+283,315
| +229% | +$29.5M | 0.01% | 1146 |
|
|
2022
Q4 | $14.7M | Sell |
123,467
-856
| -0.7% | -$100K | 0.01% | 1001 |
|
|
2022
Q3 | $13.2M | Sell |
124,323
-1,903
| -2% | -$193K | 0.01% | 1000 |
|
|
2022
Q2 | $12.3M | Buy |
126,226
+5,784
| +5% | +$534K | 0.01% | 1044 |
|
|
2022
Q1 | $11.3M | Buy |
120,442
+35,452
| +42% | +$3M | 0.01% | 1140 |
|
|
2021
Q4 | $7.24M | Sell |
84,990
-13,160
| -13% | -$1.21M | ﹤0.01% | 1387 |
|
|
2021
Q3 | $9.41M | Buy |
98,150
+7,127
| +8% | +$673K | 0.01% | 1184 |
|
|
2021
Q2 | $8.86M | Buy |
91,023
+2,474
| +3% | +$237K | 0.01% | 1204 |
|
|
2021
Q1 | $8.61M | Buy |
88,549
+8,621
| +11% | +$904K | 0.01% | 1130 |
|
|
2020
Q4 | $7.66M | Buy |
79,928
+374
| +0.5% | +$36.1K | 0.01% | 1053 |
|
|
2020
Q3 | $7.65M | Buy |
79,554
+32,384
| +69% | +$3.75M | 0.01% | 931 |
|
|
2020
Q2 | $5.75M | Buy |
47,170
+3,728
| +9% | +$412K | 0.01% | 1057 |
|
|
2020
Q1 | $3.76M | Buy |
43,442
+7,286
| +20% | +$713K | ﹤0.01% | 1131 |
|
|
2019
Q4 | $3.89M | Buy |
36,156
+1,010
| +3% | +$106K | ﹤0.01% | 1266 |
|
|
2019
Q3 | $3.17M | Buy |
35,146
+4,027
| +13% | +$376K | ﹤0.01% | 1293 |
|
|
2019
Q2 | $2.63M | Buy |
31,119
+2,829
| +10% | +$232K | ﹤0.01% | 1393 |
|
|
2019
Q1 | $2.49M | Buy |
28,290
+8,287
| +41% | +$693K | ﹤0.01% | 1360 |
|
|
2018
Q4 | $1.43M | Buy |
+20,003
| New | +$1.92M | ﹤0.01% | 1528 |
|
|
2018
Q3 | – | Sell |
-497
| Closed | -$49K | – | 2112 |
|
|
2018
Q2 | $49K | Buy |
497
+92
| +23% | +$8.23K | ﹤0.01% | 2213 |
|
|
2018
Q1 | $34K | Buy |
405
+53
| +15% | +$4.48K | ﹤0.01% | 2253 |
|
|
2017
Q4 | $27K | Sell |
352
-25
| -7% | -$1.71K | ﹤0.01% | 2468 |
|
|
2017
Q3 | $23K | Sell |
377
-386
| -51% | -$20.4K | ﹤0.01% | 2468 |
|
|
2017
Q2 | $35K | Sell |
763
-80
| -9% | -$3.88K | ﹤0.01% | 2454 |
|
|
2017
Q1 | $36K | Buy |
843
+142
| +20% | +$6.08K | ﹤0.01% | 2522 |
|
|
2016
Q4 | $27K | Sell |
701
-340
| -33% | -$15.4K | ﹤0.01% | 2600 |
|
|
2016
Q3 | $53K | Buy |
+1,041
| New | +$51.8K | ﹤0.01% | 2576 |
|
|
2016
Q1 | – | Sell |
-1,260
| Closed | -$71K | – | 3136 |
|
|
2015
Q4 | $71K | Sell |
1,260
-152
| -11% | -$7.72K | ﹤0.01% | 2522 |
|
|
2015
Q3 | $56K | Buy |
+1,412
| New | +$68.2K | ﹤0.01% | 2599 |
|
|
2014
Q4 | – | Sell |
-35
| Closed | -$1K | – | 2648 |
|
|
2014
Q3 | $1K | Hold |
35
| – | – | ﹤0.01% | 2624 |
|
|
2014
Q2 | $1K | Hold |
35
| – | – | ﹤0.01% | 2605 |
|
|
2014
Q1 | $1K | Buy |
+35
| New | +$599 | ﹤0.01% | 2431 |
|
Other funds holding NBIX
SAM
PBBUPS
AS
Envestnet Asset Management's NBIX Position: Q2 2026 in Review
Envestnet Asset Management increased its Neurocrine Biosciences (NBIX) stake by 20% in Q2 2026, buying an estimated $6.45M and bringing the position to 262,192 shares worth $44.2M. The position accounts for 0.01% of the portfolio, ranked #932.
Envestnet Asset Management first reported a position in NBIX in Q1 2014 and has held it in 44 quarters since. 292 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Envestnet Asset Management held 262,192 shares of Neurocrine Biosciences worth $44.2M as of Q2 2026.
- Envestnet Asset Management bought 43,482 Neurocrine Biosciences shares in Q2 2026, an estimated $6.45M.
- Neurocrine Biosciences made up 0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #932 holding.
- Envestnet Asset Management first reported a position in Neurocrine Biosciences in Q1 2014 and has held it in 44 quarters since.
- 292 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.